Literature DB >> 9950500

Combining endovascular and neurosurgical treatments of high-risk dural arteriovenous fistulas in the lateral sinus and the confluence of the sinuses.

K Goto1, P Sidipratomo, N Ogata, T Inoue, H Matsuno.   

Abstract

OBJECT: The authors describe the use of a systemic approach to treat dural arteriovenous fistulas (DAVFs) in the lateral sinus and the confluence of sinuses in 17 patients who presented with signs and symptoms related to intracranial hemorrhage, infarction, and diffuse brain swelling.
METHODS: Angiographic examination revealed three different types of DAVFs in these high-risk patients: 1) extremely high flow DAVF not associated with sinus occlusion or leptomeningeal retrograde venous drainage (LRVD); 2) localized DAVF with exclusive LRVD and without sinus occlusion; and 3) diffuse DAVF with sinus occlusion and LRVD. Because of the complex nature of these lesions, the authors adopted a staged protocol in which they combined endovascular and surgical treatments.
CONCLUSIONS: The authors believe that by close collaboration between endovascular therapists and vascular neurosurgeons, high-risk DAVFs in the lateral sinus and the confluence of sinuses can be successfully managed without treatment-related morbidity and mortality.

Entities:  

Mesh:

Year:  1999        PMID: 9950500     DOI: 10.3171/jns.1999.90.2.0289

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

Review 1.  Intracranial dural arteriovenous fistulas: classification, imaging findings, and treatment.

Authors:  D Gandhi; J Chen; M Pearl; J Huang; J J Gemmete; S Kathuria
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-12       Impact factor: 3.825

2.  Efficacy of DynaCT digital angiography in the detection of the fistulous point of dural arteriovenous fistulas.

Authors:  T Hiu; N Kitagawa; M Morikawa; K Hayashi; N Horie; Y Morofuji; K Suyama; I Nagata
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-12       Impact factor: 3.825

Review 3.  Recurrence of the cavernous sinus dural arteriovenous fistula at adjacent sinuses following repeated transvenous embolizations: case report and literature review.

Authors:  Takeshi Hiu; Nobutaka Horie; Kentaro Hayashi; Naoki Kitagawa; Minoru Morikawa; Junichi Kawakubo; Keisuke Tsutsumi; Kazuhiko Suyama; Izumi Nagata
Journal:  Radiat Med       Date:  2008-09-04

Review 4.  Radiosurgery for intracranial dural arteriovenous fistulas (DAVFs): a review.

Authors:  Ioannis Loumiotis; Giuseppe Lanzino; David Daniels; Jason Sheehan; Michael Link
Journal:  Neurosurg Rev       Date:  2011-05-17       Impact factor: 3.042

5.  Transvenous embolization of dural carotid cavernous fistulas: a series of 44 consecutive patients.

Authors:  K Yoshida; M Melake; H Oishi; M Yamamoto; H Arai
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-03       Impact factor: 3.825

6.  Endovascular management of dural arteriovenous fistulas of the transverse and sigmoid sinus in 150 patients.

Authors:  M Kirsch; T Liebig; D Kühne; H Henkes
Journal:  Neuroradiology       Date:  2009-04-08       Impact factor: 2.804

7.  MR angiography of dural arteriovenous fistulas: diagnosis and follow-up after treatment using a time-resolved 3D contrast-enhanced technique.

Authors:  S Meckel; M Maier; D San Millan Ruiz; H Yilmaz; K Scheffler; E-W Radue; S G Wetzel
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

8.  Treatment of dural arteriovenous fistulas.

Authors:  Vasilios Katsaridis
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 9.  Dural arteriovenous fistulas.

Authors:  Eva Neumaier-Probst
Journal:  Klin Neuroradiol       Date:  2009-05-15

10.  Pre- and post-treatment MR imaging and single photon emission CT in patients with dural arteriovenous fistulas and retrograde leptomeningeal venous drainage.

Authors:  Yutaka Kai; Jun-ichiro Hamada; Motohiro Morioka; Tatemi Todaka; Takamasa Mizuno; Yukitaka Ushio
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.